Vilon

At a glance

Standard Protocol

Alternative Titration 1: 5-Day Monthly Cycle Gradual Titration (Goal: sustained year-round immune maintenance; first-time users or subjects sensitive to immune activation)

Alternative Titration 2: 10-Day Quarterly Cycle (Goal: general immunosenescence reversal and aging immune normalization on a quarterly schedule)

Alternative Titration 3: Pre-Vaccination Immune Priming (Goal: maximize vaccine immunogenicity in aging or immunosenescent subjects by restoring naive T-cell output before antigen exposure)

Alternative Titration 4: Post-Chemotherapy Immune Reconstruction (Goal: rebuild thymopoiesis and naive T-cell output following chemotherapy-induced lymphopenia; minimum 4 weeks post-chemotherapy, ANC > 1.0)

Alternative Titration 5: Longevity Stack Integration with Epithalon + Crystagen (Goal: biannual deep immunosenescence reversal as part of comprehensive Khavinson anti-aging protocol)

Bioregulator protocols are often cycle-based because the claim is organ-system signaling rather than acute symptom control. The logic should be organ-specific labs, medical context, and humility about older or vendor-derived evidence. Entry context: target (Thymus); route Subcutaneous; timing Anytime. Unapproved or source-dataset dosing tables are hypotheses, not recommendations.

• Transient immune activation symptoms: as T-cell output normalizes and immune competence is restored, some subjects experience mild flu-like symptoms (low-grade fatigue, mild myalgia) in the first days of a new cycle; reflects immune system reactivation rather than infection or adverse response.
• Mild injection site reaction: standard subcutaneous dipeptide injection response; minimal due to the small molecular size of Vilon.
• Transient mood changes: the neuroimmune cross-regulation between the thymus and the CNS/HPA axis means thymic bioregulator activity can produce subtle mood shifts in some subjects during the active cycle; typically mild and transient.
• Potential worsening of subclinical autoimmune conditions: immune normalization in subjects with undiagnosed autoimmune predisposition could unmask or mildly exacerbate previously subclinical autoimmune processes as immune surveillance and T-cell reactivity are restored.
• No serious adverse events documented in the Khavinson research literature: the 40+ year Russian clinical use history of Vilon at standard protocol doses has not produced documented serious adverse events; the safety profile is considered excellent in the eligible (aging, immunosenescent, non-transplant, non-active-autoimmune) population.
• Unknown interaction profile with modern biologic immunomodulatory drugs: Vilon's research predates the modern biologic immunotherapy era; interactions with checkpoint inhibitors, monoclonal antibodies, and targeted immunomodulators are not characterized.

• Organ transplant recipients on immunosuppressive therapy: Vilon's T-cell restoration and thymopoietic stimulation directly counteracts the immunosuppressive regimens (calcineurin inhibitors, mTOR inhibitors, corticosteroids) required to prevent allograft rejection; restored T-cell activity increases the risk of acute and chronic rejection; absolute contraindication.
• Active autoimmune disease in acute flare: the immune normalization activity of Vilon, while not non-specific immunostimulation, could exacerbate the T-cell-mediated pathology driving active autoimmune flares in conditions such as rheumatoid arthritis, lupus, multiple sclerosis, or inflammatory bowel disease; use during active flare requires medical supervision.
• Concurrent immunosuppressive therapy for non-transplant indications (high-dose corticosteroids, methotrexate, azathioprine, biologic immunosuppressants): Vilon's immunoregulatory activity works against the therapeutic intent of these medications.
• Known hypersensitivity to Vilon (Lys-Glu dipeptide) or formulation excipients.
• Active hematological malignancies involving T-cell lineages (T-cell lymphoma, T-cell leukemia): Vilon's thymopoietic stimulation in the context of malignant T-cell clonal expansion could theoretically support tumor cell proliferation.
• Pregnancy: immune regulation changes substantially during pregnancy; exogenous thymic bioregulator activity during gestation is not characterized.
• Pediatric use in subjects with intact thymic function: the thymus is highly active in children and young adults; Vilon's therapeutic target (the involuted aging thymus) does not exist in young subjects and the effects of superimposed thymic bioregulator stimulation on normally functioning thymopoiesis are not established.

Synergistic / related

• https://the source dataset.com/peptide-codex.php
• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
• https://pubmed.ncbi.nlm.nih.gov/?term=Vilon